Mabpharm Limited (HKG:2181)
Hong Kong · Delayed Price · Currency is HKD 0.4550
+0.0150 (3.41%)
Apr 17, 2026, 3:26 PM HKT
Mabpharm Market Cap
Mabpharm has a market cap or net worth of 1.81 billion as of April 17, 2026. Its market cap has decreased by -8.33% in one year.
Market Cap
1.81B
Enterprise Value
2.06B
Revenue
718.98M
Ranking
n/a
PE Ratio
39.54
Stock Price
0.46
Market Cap Chart
Since May 31, 2019, Mabpharm's market cap has decreased from 4.99B to 1.81B, a decrease of -63.64%. That is a compound annual growth rate of -13.67%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Apr 16, 2026 | 1.81B | -12.00% |
| Dec 31, 2025 | 2.06B | 78.57% |
| Dec 31, 2024 | 1.15B | -39.13% |
| Dec 29, 2023 | 1.90B | 5.75% |
| Dec 30, 2022 | 1.79B | -56.50% |
| Dec 31, 2021 | 4.12B | -4.76% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| May 31, 2019 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| ImmuneOnco Biopharmaceuticals (Shanghai) | 2.61B |
| SinoMab BioScience | 2.34B |
| Immunotech Biopharm | 2.27B |
| Frontage Holdings | 2.07B |
| HighTide Therapeutics | 2.05B |
| Cutia Therapeutics | 1.71B |
| Hangzhou Jiuyuan Genetic Biopharmaceutical | 1.70B |
| Zhaoke Ophthalmology | 1.67B |